002370 亚太药业
2025/122024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)9.2054.409-2.693-36.144-41.757
总资产报酬率 ROA (%)7.1832.419-0.804-8.466-12.799
投入资产回报率 ROIC (%)7.6612.597-0.876-9.195-14.103

边际利润分析
销售毛利率 (%)33.11231.16832.09335.77737.881
营业利润率 (%)28.0096.949-15.085-31.216-63.256
息税前利润/营业总收入 (%)37.89513.3605.198-25.200-56.270
净利润/营业总收入 (%)29.8048.451-2.824-35.532-72.439

收益指标分析
经营活动净收益/利润总额(%)-46.850-72.316551.94149.78676.828
价值变动净收益/利润总额(%)156.658160.806-32.98212.324-10.893
营业外收支净额/利润总额(%)6.14318.356-448.72913.85111.073

偿债能力分析
流动比率 (X)5.9012.2945.9034.5194.650
速动比率 (X)5.1962.1255.3504.0904.366
资产负债率 (%)12.45830.64659.36280.23073.121
带息债务/全部投入资本 (%)5.99125.06752.49971.12264.228
股东权益/带息债务 (%)1,559.255294.93583.67730.46945.068
股东权益/负债合计 (%)702.686226.30668.45924.64136.760
利息保障倍数 (X)4.7062.7550.654-2.283-3.786

营运能力分析
应收账款周转天数 (天)104.01377.66472.13376.650107.158
存货周转天数 (天)147.721103.010116.376117.159115.651